The Board and Management of VivaZome Therapeutics – Ian Nisbet, Craig Newton, David Haylock and Xenia Sango – have over 120 years of combined biotech, cell biology and pharmaceutical experience with activity in Australia, Asia, North America, Europe, the Middle East and Central America.
Ian Nisbet has over 30 years experience in biologicals and biotech.Ian was previously CEO/MD of Xenome Ltd and Meditech Research Ltd and has held senior management positions at Millennium Pharmaceuticals Inc in US, ChemGenex Pharmaceuticals Ltd and CSL Ltd. Ian is currently Chairman at VivoPharm Pty Ltd, a director at 4 biotechs and Chief Operating Officer at Cartherics, a cell therapy company.
Craig Newton has more than 30 years experience in the Healthcare industry, notably in the Medical Device, Pharmaceutical and Biotech sectors, with activity in Australasia, Asia and Europe. His experience encompasses diverse therapeutic areas, including cardiovascular disease oncology, haematology, cell therapies, fertility and immunology. Organizations have included CSL, Serono UK, CSIRO, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals, with roles of “Chief Operating Officer”, “Sales and Marketing Director” and “Business Unit Manager”.
Chief Executive Officer
Professor David Haylock has over 35 years experience in cell biology, cell therapies and operational management with senior scientific leadership roles at CSIRO, the Australian Stem Centre, the Peter MacCallum Cancer Centre and Adelaide’s Institute of Medical and Veterinary Science. He has extensive expertise in the biology of human stem and progenitor cells, and was part of the team that pioneered autologous transplantation with mobilised blood progenitor cells, which revolutionised ‘bone marrow’ transplantation. At CSIRO, as Cell Biology Group Leader, he worked on the development of bioreactor technology for cell growth and on new polymer materials for growing stem cells. David holds an Adjunct Professorial position at the Australian Regenerative Medicine Institute at Monash University and was a previous ARC Future Fellow. He has a Bachelor of Applied Science (SAIT) and a PhD (University of Adelaide).
Clinical and Regulatory Consultant
Xenia Sango is a highly experienced healthcare executive and independent consultant with over 25 years in senior clinical, regulatory and international commercialisation roles. Xenia’s positions at CSL Limited included Senior Director of Influenza Commercial Operations; Director of International Registrations, and Head of Regulatory Affairs. Xenia’s experience included registration of the novel therapeutic rec Factor VIII in Australia and New Zealand, setting up CSL’s global regulatory function, and launching CSL’s Fluvax in US and Europe, including establishing subsidiaries in USA and Germany. In Japan, Xenia set up commercial and manufacturing operations for CSL. As Business Development Manager Research at Epworth HealthCare, Xenia expanded the research business, managed the Clinical Research Unit and set up Phase 1b capability.